The Science behind AGS-003
The proprietary process uses RNA isolated from the patient sample to program autologous dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma and administered as a simple intradermal injection rather than an intravenous bolus or infusion.
AGS-003 is an active cancer immunotherapy which has demonstrated the potential to reverse tumor induced immunosuppression and trigger a durable memory T cell response.
AGS-003 is designed to induce a specific immune response characterized by the expansion of cytotoxic CD8+ central and effector memory T-cells.